Byoung Joo Gwag, CEO of GNT Pharma

GNT Pharma was founded in 1998 with the aim of contributing to health of patients and society by developing innovative medicines for the treatment of refractory neurological diseases such as stroke or Alzheimer’s disease. GNT Pharma's research team has been committed to the development of pharmaceutical drugs rooted in a new paradigm for the treatment of stroke and neurodegenerative diseases. In particular, we specialize in establishing disease-specific multi-path brain cell death, to lead drug development that protects brain cells through disease-selective “multi-targeting” neuroprotective action. For nelonemdaz, GNT Pharma's first multi-targeting new drug for stroke, a Phase II clinical study for acute stroke has been successfully completed, and a Phase III clinical study is completed in Korea. Significant results were obtained from stroke patients who received the drug within 60 minutes of arriving at the emergency room. We are now preparing for global Phase III clinical trials. GNT Pharma's second multi-targeting new drug, crisdesalazine, is being developed for the treatment of neurodegenerative brain diseases. Crisdesalazine has completed Phase 1b trials and received approval from the Korean Ministry of Food and Drug Safety (MFDS) for a Phase II clinical trial in Alzheimer's disease. A third new drug candidate, flusalazine, is aimed at chronic obstructive pulmonary disease (COPD) and asthma; an Investigational New Drug (IND) application is being prepared to enable clinical study. GedaCure, GNT Pharma's first commercialized medicine, gained approval from the Animal and Plant Quarantine Agency as Korea’s first new synthetic veterinary drug, determined to be safe and effective in improving memory and daily activities in pet dogs with canine cognitive dysfunction syndrome (CCDS), a canine analog of human Alzheimer’s disease. GedaCure was launched in the Korean market in May 2021 through a partnership between GNT Pharma and Yuhan Corporation and is now available through prescription in approximately 1,900 animal hospitals. GNT Pharma is actively negotiating with international veterinary pharmaceutical companies for the global marketing of Gedacure. We believe it has the potential to become a major global veterinary medicine drug by 2025. The success of Gedacure bodes well for GNT’s multitargeting approach to drug discovery and for the future clinical success of nelonemdaz, crisdesalazine, and flusalazine. GNT Pharma will continue to dedicate the enthusiasm and hard work of its talented workforce to bring these and other new treatments forward to benefit patients and society, as well as animals, worldwide.